论文部分内容阅读
Background: Topiramate is a broad-spectrum agent effective against primarily generalized tonic-clonic seizures (PGTCS) as well as partial-onset seizures. Juvenile myoclonic epilepsy is one of the most common idiopathic generalized epilepsies, with most patients experiencing PGTCS. Objective: To evaluate topiramate as add-on therapy in patients with juvenile myoclonic epilepsy. Design: Post-hoc analysis of a patient subset from 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group trials. Setting: Eighteen centers in the United States; 10 centers in Europe; 1 center in Costa Rica (primary trials). Patients: A total of 22 patients with juvenile myoclonic epilepsy participating in placebo-controlled trials assessing topiramate (target dose, 400 mg/d in adults)in inadequately controlled PGTCS. Main Outcome Measure: Reduction of PGTCS. Results: A 50% or more reduction of PGTCS in 8 of 11 topiramate-treated patients (73% ) and 2 of 11 placebo-treated patients (18% ) (P=.03). Reductions in myoclonic, absence, and total generalized seizures were also observed, although topiramate vs placebo differences did not achieve statistical significance. Conclusion: As a broad-spectrum agent, topiramate is an effective option for patients with juvenile myoclonic epilepsy.
Background: Topiramate is a broad-spectrum agent effective againstranes generalized tonic-clonic seizures (PGTCS) as well as partial-onset seizures. Juvenile myoclonic epilepsy is one of the most common idiopathic generalized epilepsies, with most patients experiencing PGTCS. Objective: To evaluate topiramate as add-on therapy in patients with juvenile myoclonic epilepsy. Design: Post-hoc analysis of a patient subset from 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group trials. Setting: Eighteen centers in the United 10 centers in Europe; 1 center in Costa Rica (primary trials). Patients: A total of 22 patients with juvenile myoclonic epilepsy participating in placebo-controlled trials assessing topiramate (target dose, 400 mg / d in adults) in inadequately controlled PGTCS. Main Outcome Measure: Reduction of PGTCS. Results: A 50% or more reduction of PGTCS in 8 of 11 topiramate-treated patients (73%) and 2 of 11 placebo-treated patients (18% .03). Reductions in myoclonic, absence, and total generalized seizures were also observed, although topiramate vs placebo disorders did not achieve statistical significance. Conclusion: As a broad-spectrum agent, topiramate is an effective option for patients with juvenile myoclonic epilepsy.